

CD3 antigen inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/C06FA70E9094EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C06FA70E9094EN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "CD3 Antigen Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in CD3 Antigen Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

CD3 Antigen Inhibitors Understanding

CD3 Antigen Inhibitors: Overview

Cluster of differentiation 3 (CD3) is a multimeric protein complex, known historically as the T3 complex, and is composed of four distinct polypeptide chains; epsilon (?), gamma (?), delta (?) and zeta (?), that assemble and function as three pairs of dimers (??, ??, ??). The CD3 complex serves as a T cell co-receptor that associates noncovalently with the T cell receptor

Function - In immunology, Cluster of differentiation 3 as T-cell co-receptor helps to activate the cytotoxic T-Cell. CD3 consists of a protein complex and is composed of four distinct chains. These chains associate with a molecule known as the T-cell receptor (TCR) and the ϵ -chain (zeta-chain) to generate an activation signal in T lymphocytes.

The TCR, ϵ -chain, and CD3 molecules together constitute the TCR complex. The complex functions to transduce intracellular signals during TCR antigen recognition. CD3 epsilon is one of at least three invariant proteins that associate with the variable antigen recognition chains of the T cell receptor and function in signal transduction.

CD3 Antigen Inhibitors - The CD3 protein complex is an important T cell marker for the classification of malignant lymphomas and leukemias (T cell neoplasms). CD3 can also be used for the identification of T cells in coeliac disease, lymphocytic colitis and collagenous colitis. Animal studies have shown that anti-CD3 antibodies induce tolerance to allografts (Nicolls et al. 1993). OKT3, an anti-CD3 antibody directed against CD3 ϵ , has been clinically approved for use in humans for the induction of immunosuppression in solid organ transplantation for the prevention and treatment of rejection. Interestingly, susceptibility to type I diabetes has been associated with the CD3 ϵ genetic locus and anti-CD3 antibodies have been shown to ameliorate the symptoms of this and other auto-immune disorders. New anticancer drug treatments are being developed based upon the CD3 (cluster of differentiation 3) T cell co-receptor, with molecules being designed for altering the co-stimulatory signal to help get the T-cell to recognize the cancer cell and become fully activated.

CD3 Antigen Inhibitors Emerging Drugs Chapters

This segment of the CD3 Antigen Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CD3 Antigen Inhibitors Emerging Drugs

Tebentafusp: Immunocore

Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore's ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK

Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently in phase 3 stage of development.

Cibisatamab: Roche

Cibisatamab is an intravenously administered T-cell bispecific monoclonal antibody, being developed by Roche for the treatment of Non-small cell lung cancer. Currently, it is in phase I/II stage of development.

Further product details are provided in the report.....

CD3 Antigen Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different CD3 Antigen Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on CD3 Antigen Inhibitors

There are approx. 20+ key companies which are developing the CD3 Antigen Inhibitors. The companies which have their CD3 Antigen Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Immunocore.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

CD3 Antigen Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CD3 Antigen Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD3 Antigen Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD3 Antigen Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence CD3 Antigen Inhibitors R&D. The therapies under development are focused on novel approaches for CD3 Antigen Inhibitors.

CD3 Antigen Inhibitors Report Insights

CD3 Antigen Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

CD3 Antigen Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing CD3 Antigen Inhibitors drugs?

How many CD3 Antigen Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for CD3 Antigen Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD3 Antigen Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for CD3 Antigen Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Immunocore

Roche

Janssen Research & Development

Celgene Corporation

Avacta

MacroGenics

BioNTech

Pfizer

EpimAb Biotherapeutics

Glenmark Pharmaceuticals

Tiziana Life Sciences

IGM Biosciences

QLSF Biotherapeutics

Y-mAbs Therapeutics

Genmab

YZY Biopharma

Abzyme Therapeutics

Harbour BioMed

Aptevo Therapeutics

IONTAS

TeneoBio

Cullinan Oncology

Key Products

Tebentafusp

Cibisatamab

JNJ 78278343

AVA 002

MGD 014

Glofitamab

BNT142

PF-06863135

JNJ-64007957

EMB-06

EMB-07

GBR 1302

GBR 1342

GBR 1372

Foralumab

IGM-2323

QL315

QL325

Nivatrotamab

huCD33-BsAb

Epcoritamab

M802

HBM7020

APVO436

TNB-486

Teclistamab

CLN-049

CLN-978

Contents

Introduction

Executive Summary

CD3 Antigen Inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

CD3 Antigen Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

CD3 Antigen Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value

Trends

CD3 Antigen Inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Tebentafusp: Immunocore

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Teclistamab: Janssen Research & Development

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

Cibisatamab: Roche

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

BNT 142: BioNTech

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

CD3 Antigen Inhibitors Key Companies

CD3 Antigen Inhibitors Key Products

CD3 Antigen Inhibitors- Unmet Needs

CD3 Antigen Inhibitors- Market Drivers and Barriers

CD3 Antigen Inhibitors- Future Perspectives and Conclusion

CD3 Antigen Inhibitors Analyst Views

CD3 Antigen Inhibitors Key Companies

Appendix

I would like to order

Product name: CD3 antigen inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/C06FA70E9094EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C06FA70E9094EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970